Efficacy and safety of coadministration of once-daily indacaterol and glycopyrronium versus indacaterol alone in COPD patients: the GLOW6 study

BACKGROUND: Addition of a second bronchodilator from a different pharmacological class may benefit patients with moderate-to-severe chronic obstructive pulmonary disease (COPD) whose symptoms are insufficiently controlled by bronchodilator monotherapy. GLOW6 evaluated the efficacy and safety of once...

Descripción completa

Detalles Bibliográficos
Autores principales: Vincken, Walter, Aumann, Joseph, Chen, Hungta, Henley, Michelle, McBryan, Danny, Goyal, Pankaj
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2014
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3940646/
https://www.ncbi.nlm.nih.gov/pubmed/24596459
http://dx.doi.org/10.2147/COPD.S51592

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3940646/
https://www.ncbi.nlm.nih.gov/pubmed/24596459
http://dx.doi.org/10.2147/COPD.S51592

Ejemplares similares